메뉴 건너뛰기




Volumn 8, Issue 2, 2011, Pages 125-135

Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus

Author keywords

Dipeptidyl peptidase 4; DPP 4 inhibitor; HbA1C; Saxagliptin; Thiazolidinedione; Type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN;

EID: 79959217544     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164111404575     Document Type: Article
Times cited : (58)

References (25)
  • 1
    • 64649104158 scopus 로고    scopus 로고
    • Banting Lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus
    • DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-795.
    • (2009) Diabetes , vol.58 , pp. 773-795
    • DeFronzo, R.A.1
  • 2
    • 0032511583 scopus 로고    scopus 로고
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
    • UK Prospective Diabetes Study (UKPDS) Group
    • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
    • (1998) Lancet , vol.352 , pp. 837-853
  • 3
    • 0032983666 scopus 로고    scopus 로고
    • Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49)
    • UK Prospective Diabetes Study (UKPDS) Group
    • Turner RC, Cull CA, Frighi V, Holman RR and UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
    • (1999) JAMA , vol.281 , pp. 2005-2012
    • Turner, R.C.1    Cull, C.A.2    Frighi, V.3    Holman, R.R.4
  • 7
    • 64749100501 scopus 로고    scopus 로고
    • Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
    • Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R and Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
    • (2009) Diabetes Care , vol.32 , pp. 193-203
    • Nathan, D.M.1    Buse, J.B.2    Davidson, M.B.3    Ferrannini, E.4    Holman, R.R.5    Sherwin, R.6    Zinman, B.7
  • 8
    • 75549091263 scopus 로고    scopus 로고
    • Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology Consensus Panel on type 2 diabetes mellitus: An algorithm for glycemic control
    • Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, et al. Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology Consensus Panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocrine Practice 2009; 15: 541-559.
    • (2009) Endocrine Practice , vol.15 , pp. 541-559
    • Rodbard, H.W.1    Jellinger, P.S.2    Davidson, J.A.3    Einhorn, D.4    Garber, A.J.5    Grunberger, G.6
  • 10
    • 67449103220 scopus 로고    scopus 로고
    • Redefining the role of thiazolidinediones in the management of type 2 diabetes
    • Barnett AH. Redefining the role of thiazolidinediones in the management of type 2 diabetes. Vasc Health Risk Manag 2009; 5: 141-151.
    • (2009) Vasc Health Risk Manag , vol.5 , pp. 141-151
    • Barnett, A.H.1
  • 11
    • 74549198914 scopus 로고    scopus 로고
    • Bristol-Myers Squibb Company AstraZeneca Pharmaceuticals LP. Princeton, NJ/Wilmington, DE, Bristol-Myers Squibb Company/AstraZeneca Pharmaceuticals LP
    • Bristol-Myers Squibb Company AstraZeneca Pharmaceuticals LP. Onglyza [package insert]. Princeton, NJ/Wilmington, DE, Bristol-Myers Squibb Company/AstraZeneca Pharmaceuticals LP, 2009.
    • (2009) Onglyza [Package Insert]
  • 12
    • 70549096922 scopus 로고    scopus 로고
    • Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition
    • Kirby M, Ming Tse Yu D, O'Connor S and Gorrell M. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci 2010; 118: 31-41.
    • (2010) Clin Sci , vol.118 , pp. 31-41
    • Kirby, M.1    Ming Tse Yu, D.2    O'Connor, S.3    Gorrell, M.4
  • 13
    • 77951758117 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus
    • Neumiller JJ, Wood L and Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010; 30: 463-484.
    • (2010) Pharmacotherapy , vol.30 , pp. 463-484
    • Neumiller, J.J.1    Wood, L.2    Campbell, R.K.3
  • 14
    • 77951702763 scopus 로고    scopus 로고
    • Safety, tolerability, pharmacokinetics and pharmacodynamics of once-daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects
    • abstract
    • Boulton D and Geraldes M. Safety, tolerability, pharmacokinetics and pharmacodynamics of once-daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects. [abstract]. Diabetes 2007; 56(suppl 1): 606P.
    • (2007) Diabetes , vol.56 , Issue.SUPPL. 1 , pp. 606
    • Boulton, D.1    Geraldes, M.2
  • 15
    • 73149084956 scopus 로고    scopus 로고
    • Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone
    • for the CV181- 013 investigators.
    • Hollander P, Li J, Allen E, Chen R and for the CV181- 013 investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009; 94: 4810-4819.
    • (2009) J Clin Endocrinol Metab , vol.94 , pp. 4810-4819
    • Hollander, P.1    Li, J.2    Allen, E.3    Chen, R.4
  • 16
    • 70349314675 scopus 로고    scopus 로고
    • Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study
    • Pratley RE, Reusch JE, Fleck PR, Wilson CA and Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2009; 25: 2361-2371.
    • (2009) Curr Med Res Opin , vol.25 , pp. 2361-2371
    • Pratley, R.E.1    Reusch, J.E.2    Fleck, P.R.3    Wilson, C.A.4    Mekki, Q.5
  • 17
    • 33751557143 scopus 로고    scopus 로고
    • Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
    • DOI 10.1016/j.clinthera.2006.10.007, PII S0149291806002475
    • Rosenstock J, Brazg R, Andryuk PJ, Lu K and Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006; 28: 1556-1568. (Pubitemid 44841980)
    • (2006) Clinical Therapeutics , vol.28 , Issue.10 , pp. 1556-1568
    • Rosenstock, J.1    Brazg, R.2    Andryuk, P.J.3    Lu, K.4    Stein, P.5
  • 18
    • 34250212715 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
    • Nissen SE and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471. (Pubitemid 46919772)
    • (2007) New England Journal of Medicine , vol.356 , Issue.24 , pp. 2457-2471
    • Nissen, S.E.1    Wolski, K.2
  • 19
    • 76349117322 scopus 로고    scopus 로고
    • Once-daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with type 2 diabetes
    • DeFronzo R, Hissa MN, Garber AJ, Gross JL, Duan RY, Ravichandran S, et al. Once-daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with type 2 diabetes. Diabetes 58(suppl 1):, 547-P.
    • Diabetes , vol.58 , Issue.SUPPL. 1
    • DeFronzo, R.1    Hissa, M.N.2    Garber, A.J.3    Gross, J.L.4    Duan, R.Y.5    Ravichandran, S.6
  • 20
    • 21344451651 scopus 로고    scopus 로고
    • Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes
    • DOI 10.1007/s00125-005-1751-1
    • Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005; 48: 1093-1104. (Pubitemid 40909644)
    • (2005) Diabetologia , vol.48 , Issue.6 , pp. 1093-1104
    • Charbonnel, B.1    Schernthaner, G.2    Brunetti, P.3    Matthews, D.R.4    Urquhart, R.5    Tan, M.H.6    Hanefeld, M.7
  • 21
    • 36448968168 scopus 로고    scopus 로고
    • Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus
    • Hermansen K and Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007; 30: 1127-1142. (Pubitemid 350172854)
    • (2007) Drug Safety , vol.30 , Issue.12 , pp. 1127-1142
    • Hermansen, K.1    Mortensen, L.S.2
  • 22
    • 34447267513 scopus 로고    scopus 로고
    • Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis
    • DOI 10.1001/jama.298.2.194
    • Amori RE, Lau J and Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298: 194-206. (Pubitemid 47057766)
    • (2007) Journal of the American Medical Association , vol.298 , Issue.2 , pp. 194-206
    • Amori, R.E.1    Lau, J.2    Pittas, A.G.3
  • 23
    • 77953108350 scopus 로고    scopus 로고
    • A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes
    • Frederich R, Alexander JH, Fiedorek FT, Donovan M, Berglind N, Harris S, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010; 122: 16-27.
    • (2010) Postgrad Med , vol.122 , pp. 16-27
    • Frederich, R.1    Alexander, J.H.2    Fiedorek, F.T.3    Donovan, M.4    Berglind, N.5    Harris, S.6
  • 24
    • 13644263258 scopus 로고    scopus 로고
    • Oral antidiabetic agents: Current role in type 2 diabetes mellitus
    • DOI 10.2165/00003495-200565030-00005
    • Krentz AJ and Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65: 385-411. (Pubitemid 40227460)
    • (2005) Drugs , vol.65 , Issue.3 , pp. 385-411
    • Krentz, A.J.1    Bailey, C.J.2
  • 25
    • 0035408779 scopus 로고    scopus 로고
    • A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes
    • Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI and Rosenstock J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24: 1226-1232. (Pubitemid 33716403)
    • (2001) Diabetes Care , vol.24 , Issue.7 , pp. 1226-1232
    • Raskin, P.1    Rendell, M.2    Riddle, M.C.3    Dole, J.F.4    Freed, M.I.5    Rosenstock, J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.